跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

555552

Sigma-Aldrich

Rho Kinase Inhibitor

InSolution, ≥95%

登录查看公司和协议定价

别名:
InSolution Rho Kinase Inhibitor
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

检测方案

≥95% (HPLC)

形式

liquid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

储存温度

−20°C

一般描述

A cell-permeable isoquinolinesulfonamide compound that acts as a highly specific, potent, and ATP-competitive inhibitor of G-protein Rho-associated kinase (ROCK; Ki = 1.6 nM). Inhibits other serine/threonine kinases only at higher concentrations (Ki = 630 nM for PKA, 9.27 µM for PKC, and 10.1 µM for MLCK). Shown to selectively block lysophosphatidic acid-induced, but not PDBu-induced, phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in NT-2 cells (IC50 = 2.5 µM). Reported to be a more potent and selective inhibitor than Y-27632 (Cat. No. 688000 & 688001).
The InSolution Rho Kinase Inhibitor controls the biological activity of Rho Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

生化/生理作用

Cell permeable: no
Primary Target
ROCK
Product competes with ATP.
Target Ki: 1.6 nM against Rho-associated kinase (ROCK)

警告

Toxicity: Harmful (C)

外形

A 10 mM (500 µg/128 µl) solution of Rho Kinase Inhibitor (Cat. No. 555550) in H₂O.

重悬

Following initial thaw, aliquot and freeze (-20°C).

其他说明

Ikenoya, M., et al. 2002. J. Neurochem.81, 9.
Sasaki, Y., et al. 2002. Pharmacol. Ther.93, 225.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

nwg

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Harini Narasimhan et al.
Biology, 11(10) (2022-10-28)
TNBC represents the most aggressive breast cancer subtype. Although cancer stem cells (CSCs) are a minor fraction of all cancer cells, they are highly cancerous when compared to their non-stem counterparts, playing a major role in tumor recurrence and metastasis.
Xiao Li et al.
International journal of molecular sciences, 21(2) (2020-01-16)
Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen and progesterone receptors (ER, PR) and lacking an overexpression of human epidermal growth factor receptor 2 (HER2). Apart from this lack of therapeutic targets
Katrin Raute et al.
Cancer immunology research, 11(6), 810-829 (2023-05-04)
There are no targeted therapies for patients with triple-negative breast cancer (TNBC). TNBC is enriched in breast cancer stem cells (BCSC), which play a key role in metastasis, chemoresistance, relapse, and mortality. γδ T cells hold great potential in immunotherapy
Jessalyn M Ubellacker et al.
Nature, 585(7823), 113-118 (2020-08-21)
Cancer cells, including melanoma cells, often metastasize regionally through the lymphatic system before metastasizing systemically through the blood1-4; however, the reason for this is unclear. Here we show that melanoma cells in lymph experience less oxidative stress and form more

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门